Search Results
Your search for ,iII matches 9601 pages
Showing 3551 - 3600Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC
Neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response (pCR) rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to results of the randomized, phase III, open-label...
Copanlisib/Rituximab Extends Progression-Free Survival vs Rituximab/Placebo in Indolent Non-Hodgkin Lymphoma
The combination of copanlisib plus rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with indolent non-Hodgkin lymphoma, according to results of the phase III CHRONOS-3 trial presented by Matthew J. Matasar, MD, at the virtual...
Tebentafusp: First Treatment to Improve Overall Survival in Metastatic Uveal Melanoma
Treatment with tebentafusp, a novel bispecific fusion protein, reduced the risk of death from metastatic uveal melanoma at 14 months by half, compared with available treatments, in a phase III study presented by Piperno-Neumann et al at the virtual American Association for Cancer Research (AACR)...
Expert Point of View: David A. Braun, MD, PhD
Invited discussant David A. Braun, MD, PhD, of Dana-Farber Cancer Institute, Boston, said there are a couple of established pillars of systemic therapy for metastatic renal cell carcinoma (RCC). “An immune checkpoint inhibitor is a strong pillar, a [vascular endothelial growth factor tyrosine...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Johan Vansteenkiste, MD, PhD, and Fiona Blackhall, PhD, FRCP, Honored for Lung Cancer Research by ESMO and IASLC
The European Society for Medical Oncology and the International Association for the Study of Lung Cancer recently presented the Heine H. Hansen Award 2021 to Johan Vansteenkiste, MD, PhD, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit...
Expert Point of View: Gillianne G.Y. Lai, MBBS
Gillianne G.Y. Lai, MBBS, of the National Cancer Centre, Singapore, discussed the presentations on novel agents for exon 20 insertion mutations in non–small cell lung cancer (NSCLC), which account for about one-third of tyrosine kinase resistance mutations. Although tyrosine kinase mutations are...
Patient-Reported Outcomes With Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
Results of the CheckMate 9ER phase III trial showed significantly improved patient-reported outcomes in quality of life for first-line treatment with nivolumab plus cabozantinib compared with sunitinib for patients with advanced renal cell carcinoma.1 These findings are in line with the previously...
Expert Point of View: Ursula Matulonis, MD
Invited discussant, Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, Boston, applauded the improved outcomes favoring lenvatinib/pembrolizumab in the confirmatory KEYNOTE-775 trial. “This represents the start of a new era in endometrial cancer...
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantly improved multiple outcomes compared with standard single-agent chemotherapy in patients with...
Clinical Breast Examination Screening Results in Lower Stage at Breast Cancer Diagnosis and Reduced Breast Cancer Mortality in India
In an Indian study reported in the British Medical Journal, Indraneel Mittra, MD, PhD, of Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, and colleagues at Tata Memorial Centre found that breast cancer screening with clinical breast examination vs active surveillance resulted in...
Outcomes With Ribociclib Across Intrinsic Subtypes of HR-Positive, HER2-Negative Breast Cancer
In an analysis of several phase III MONALEESA trials reported in the Journal of Clinical Oncology, Aleix Prat, MD, PhD, and colleagues found consistent progression-free survival benefits with the combination of ribociclib plus endocrine therapy vs placebo plus endocrine therapy across all intrinsic ...
Adverse Events in Patients With Melanoma Treated With Ipilimumab: Results of a Toxicity Monitoring Program
In a single-institution study reported in JCO Oncology Practice, Menjak et al found that a nurse-led telephone surveillance program for toxicity associated with ipilimumab in patients with metastatic melanoma led to earlier identification of toxicities and earlier intervention, with an apparent...
Second-Line FOLFOX vs Active Symptom Control in Advanced Biliary Tract Cancer
In the phase III ABC-06 trial reported in The Lancet Oncology, Angela Lamarca, PhD, and colleagues found that second-line FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) produced a statistically significant improvement in median overall survival vs active symptom control in patients with...
Oral Azacitidine in Lower-Risk Myelodysplastic Syndromes
In a phase III trial reported in the Journal of Clinical Oncology, Guillermo Garcia-Manero, MD, and colleagues found that oral azacitidine significantly improved red blood cell (RBC) transfusion independence vs placebo in patients with lower-risk myelodysplastic syndromes. An increase in early...
Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes
For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...
Pembrolizumab in Microsatellite Instability–High Advanced Gastric or Gastroesophageal Junction Cancer
In an analysis reported in JAMA Oncology, Joseph Chao, MD, and colleagues found improved outcomes with pembrolizumab treatment in patients with microsatellite instability–high (MSI-H) advanced gastric or gastroesophageal junction cancer, irrespective of line of treatment. The findings suggest that...
Overall Survival With Olaparib vs Placebo Maintenance in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and BRCA1/2 Mutation
As reported in The Lancet Oncology by Andrés Poveda, MD, and colleagues, the phase III SOLO2/ENGOT-Ov21 trial has shown a large numeric but statistically nonsignificant improvement in the secondary endpoint of overall survival with olaparib tablet maintenance therapy vs placebo in patients with...
Locally Advanced Esophageal Cancer: Neoadjuvant Chemoradiotherapy vs Chemotherapy Followed by Minimally Invasive Esophagectomy
In an early analysis from a Chinese phase III trial reported in JAMA Surgery, Wang et al found similar safety and improved histopathologic outcome among patients undergoing minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma following neoadjuvant...
Impact of COVID-19 Pandemic on Delivery of Breast Cancer Care in New York
In a single-institution retrospective study focused on a New York City location reported in JCO Oncology Practice, Satish et al found that more than 40% of patients with breast cancer not infected with COVID-19 had a delay or change in care delivery due to the pandemic. Study Details The study...
Risk of Venous and Arterial Thromboembolism in Patients With Cancer Receiving Immune Checkpoint Inhibitors
In a single-institution retrospective analysis reported in the journal Blood, Moik et al found a substantial risk of thromboembolic events in patients receiving immune checkpoint inhibitor therapy for cancer, as well as an increased risk of mortality among those experiencing venous ...
Meta-analysis Finds Liver Tumors May Be Resistant to Immunotherapy in Patients With Underlying Nonalcoholic Steatohepatitis
Immunotherapy is not only significantly less effective in patients with liver cancer who previously had nonalcoholic steatohepatitis, but it actually may fuel tumor growth, according to a study published by Pfister et al in Nature. Nonalcoholic steatohepatitis affects as many as 40 million people...
Chronic Immune-Related Adverse Events Associated With Adjuvant Immunotherapy for Advanced Melanoma
In a retrospective cohort study reported in JAMA Oncology, Patrinely et al found that chronic immune-related adverse events occurred in a high proportion of patients receiving adjuvant PD-1–targeted therapy for high-risk resected melanoma and frequently persisted even during prolonged follow-up....
FDA Approves Isatuximab-irfc Combination for Relapsed or Refractory Multiple Myeloma
On March 31, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. IKEMA The efficacy...
FDA Approves New Indication for Daunorubicin/Cytarabine: Secondary AML in Pediatric Patients
On March 30, the U.S. Food and Drug Administration (FDA) approved a revised label for the combination of daunorubicin and cytarabine (Vyxeos) to include a new indication to treat newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC) in...
Does Adding Adjuvant Concurrent Trastuzumab to Radiotherapy After Lumpectomy for HER2-Positive DCIS Reduce Ipsilateral Recurrence?
As reported in the Journal of Clinical Oncology by Cobleigh et al, the phase III NRG Oncology/NSABP B-43 trial did not show a significant reduction in ipsilateral breast tumor recurrence with the addition of adjuvant concurrent trastuzumab to radiotherapy in women undergoing lumpectomy for...
Pembrolizumab vs Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma: KEYNOTE-204 Trial
As reported in The Lancet Oncology by John Kuruvilla, MD, and colleagues, an interim analysis of the phase III KEYNOTE-204 trial has shown significantly improved progression-free survival with pembrolizumab vs brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma....
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Following Neoadjuvant Chemoradiation Therapy
Adjuvant nivolumab is the first therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer, according to research presented by Guillaume Piessen, MD, PhD, and colleagues at...
Despite Access to Clinical Trials, Patients From Socioeconomically Disadvantaged Areas Have Worse Cancer Outcomes
As reported in the Journal of Clinical Oncology by Joseph A. Unger, PhD, and colleagues, a large retrospective observational study investigating the association between socioeconomic deprivation and outcomes among patients with cancer enrolled in clinical trials has found that compared to patients...
Expert Point of View: Rutika Mehta, MD, MPH
The FIGHT study’s invited discussant, Rutika Mehta, MD, MPH, a gastrointestinal oncologist at Moffitt Cancer Center, Tampa, Florida, noted the emergence of new biomarkers and their targeted agents in HER2-negative gastric or gastroesophageal junction cancer. Two important ones are FGFR2b—now...
Targeting FGFR2b With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
Gastric cancer appears to have a new druggable target: fibroblast growth factor receptor 2b (FGFR2b). Targeting FGFR2b with bemarituzumab plus chemotherapy led to clinically meaningful and statistically significant improvements in progression-free survival, overall survival, and response rate in...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Novel CK2 Inhibitor Silmitasertib Shows Promise in Cholangiocarcinoma
A novel inhibitor of casein kinase 2 (CK2) has shown preliminary evidence of efficacy in patients with locally advanced or metastatic cholangiocarcinoma, according to a phase I/IIb study presented at the 2021 Gastrointestinal Cancers Symposium.1 Silmitasertib (CX-4945) is an oral small-molecule...
Expert Point of View: Rachna T. Shroff, MD, and Gentry King, MD
Invited study discussant Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said the study presented by Dr. Javle showed the FGFR2 inhibitor infigratinib to be active in FGFR2 fusion–positive...
FGFR2 Inhibitor Infigratinib Active in Chemotherapy-Refractory Cholangiocarcinoma
The novel targeted agent infigratinib (BGJ398) showed clinically meaningful activity against chemotherapy-refractory cholangiocarcinoma in patients with fibroblast growth factor receptor (FGFR2) fusions and rearrangements. The confirmed overall response rate was 23% (34% confirmed/unconfirmed), the ...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Improves Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–PD-L1 plus anti-VEGF therapy with...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer
In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial of pembrolizu-mab for microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to ...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. In the spring of 2020, The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing...
Gastrointestinal Oncology Highlights 2020–2021 Almanac
Cancers of the digestive tract account for 338,090 new cases and 169,280 deaths annually in the United States. Although the overall mortality from these cancers is decreasing, this has been countered by an increase in the incidence of colorectal cancer in young adults. The rising incidence and poor ...
Younger vs Older Women With Breast Cancer: Understanding the Differences
Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. At PER’s...
FDA Grants Two New Breakthrough Device Designations for Molecular Residual Disease Test
The U.S. Food and Drug Administration (FDA) granted two breakthrough device designations covering new intended uses of the Signatera molecular residual disease (MRD) test. These new designations will support the development of Signatera through phase III clinical trials as a companion diagnostic to ...
ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC
An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.1...
Cancer Control in Egypt: Investing in Health
Egypt is a country of 1,010,408 km2 located on the northeast corner of Africa with a population exceeding 100 million. In 2018, there were about 134,632 new cancer cases and 89,042 cancer-related deaths in Egypt. Liver and breast cancers are the most common tumors in terms of incidence and...
